We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Genzyme Launches EGFR FISH & JAK2 to Expand Cancer Menu

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Genzyme Genetics has offered two tests that is designed to identify non-small cell lung cancer (NSCLC) patients likely to respond to therapies.

The presence of epidermal growth factor receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva® (erlotinib) and IRESSA® (gefitinib), used in treating this deadly form of cancer.

Genzyme offers EGFR by FISH (fluorescence in-situ hybridization), which detects over amplification of the EGFR gene. This test complements Genzyme's EGFR Mutation Assay, which also detects the presence of EGFR in patients with NSCLC.

Genzyme has also made available an assay that detects a mutation in the Janus kinase 2 (JAK2) gene common in chronic myeloproliferative disorders (MPDs).